Selinexor for Relapsed/Refractory Multiple Myeloma

recent news item - Patients with relapsed/refractory multiple myeloma (RRMM) for whom prior treatment with lenalidomide, pomalidomide, bortezomib, and carfilzomib fail have few treatment options. Selinexor (KPT-330) is a selective inhibitor of nuclear export (SINE) under development for the treatment of RRMM and other advanced hematologic malignancies. Selinexor induces cell death through apoptosis and autophagy. This dual mechanism is both novel and potentially synergistic with mechanisms already acted upon by drugs used in the treatment of patients with RRMM.  (source: mmdevelopments.org)